BB Biotech (BION) Q4 2025 earnings summary

Executive summary

• Achieved net profit of CHF 578 million for 2025, up from CHF 76 million in 2024, with Q4 net profit at CHF 472 million, reflecting strong year-end momentum.

• Delivered total returns of +34.2% in CHF, +37.0% in EUR, and +53.7% in USD, outperforming the Nasdaq Biotechnology Index in USD.

• Five portfolio companies were acquired in 2025, validating the focus on clinically mature, differentiated assets.

• Proposed dividend of CHF 2.25 per share and launched a new share buyback program of up to 10% over three years.

• Portfolio strategy emphasized disciplined capital allocation, structural M&A exposure, and a catalyst-rich selection.

Financial highlights

• Net asset value increased by 26.5% in CHF, 27.8% in EUR, and 44.8% in USD for 2025.

• Share price outperformed, rising 34.2% in CHF, 37.0% in EUR, and 53.7% in USD year-over-year.

• Outperformed the Nasdaq Biotech Index, which rose 16.6% in CHF and 33.4% in USD.

• Discount to NAV narrowed from 15.2% to 10.8% at year-end 2025, further tightening to 8% in early 2026.

• Portfolio ended 2025 with CHF 2,681.9 million in securities and a NAV of CHF 2,778.8 million.

Outlook and guidance

• Entering 2026 with a diversified set of high-impact milestones across core positions, reducing dependence on single binary events.

• Portfolio positioned for late-stage clinical, regulatory, and commercial milestones in 2026, with focus on immunology, oncology, and rare diseases.

• Expecting a catalyst-rich year with multiple phase III data readouts and commercial launches in key portfolio companies.

• Continued focus on clinically mature, strategically relevant assets aligned with big pharma needs.

• Proposed dividend of CHF 2.25 per share and new share buyback program up to 10% over three years.